Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma.
Histone deacetylases (HDACs) are enzymes that are involved in the remodeling of chromatin and play a key role in the epigenetic regulation of gene expression. In addition, the activity of non-histone proteins can be regulated through HDAC-mediated hypoacetylation. In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes associated with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anti-cancer activities in preclinical studies. Many researchers have highlighted the need to determine specific HDAC isotypes related to different tumor types in order to develop selective drugs for specific isoforms and avoid side effects. We summarize recent advances in the understanding of the molecular events that underlie the epigenetic changes in different tissue carcinomas, focusing on oral squamous carcinoma. The role of epigenetics in oral squamous cancer remains poorly understood, and further descriptive studies of specific HDAC member alterations are required to form the basis for future clinical trials.
Iglesias-Linares
A
A
Dentistry Biomedical Research Department, University of Seville, 41009 Seville, Spain. brpi@us.es
Yañez-Vico
R M
RM
González-Moles
M A
MA
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000201:enzymology; D044127:Epigenesis, Genetic / Q000187:drug effects*; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006655:Histone Deacetylases / Q000502:physiology; D006801:Humans; D008297:Male; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D011379:Prognosis
D056572:Histone Deacetylase Inhibitors; D009363:Neoplasm Proteins; D006655:Histone Deacetylases